Jove
Visualize
联系我们

相关概念视频

Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

200
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
200
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

207
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
207
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

101
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
101
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

161
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
161
Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

1.9K
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
1.9K
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

152
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
152
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
  1. 首页
  2. 防晒对防晒活性成分度的影响:随机临床试验
  1. 首页
  2. 防晒对防晒活性成分度的影响:随机临床试验

相关实验视频

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.7K

防晒对防晒活性成分度的影响:随机临床试验

Murali K Matta1, Jeffry Florian1, Robbert Zusterzeel1

  • 1Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.

JAMA
|January 22, 2020

在PubMed 上查看摘要

概括
此摘要是机器生成的。

六种防晒剂的系统吸收得到证实,在第一天的血度超过了FDA的0. 5 ng/ ml的值. 这些关于防晒成分的发现并不能保证避免使用防晒.

更多相关视频

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

18.7K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.0K

相关实验视频

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

42.7K
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

18.7K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.0K

科学领域:

  • 皮肤病学
  • 药物动力学
  • 毒理学

背景情况:

  • 一项先前的试点研究表明,四种防晒的活性成分被全身吸收.
  • 需要进一步的研究来评估其他活性成分及其吸收率.
  • 了解系统吸收对于美国食品和药物管理局 (FDA) 的监管评估至关重要.

研究的目的:

  • 评估六种主要防晒活性成分的全身吸收和药理动力学.
  • 为了比较四种不同的防晒配方在一次性和最大使用条件下的吸收.
  • 为了确定血度是否超过FDA的0.5 ng/mL值.

主要方法:

  • 进行了一项随机临床试验,涉及48名健康参与者.
  • 参与者使用四种防晒剂之一 (乳液,气溶喷雾,非气溶喷雾,喷雾) 给定剂量.
  • 在21天内采集血液样本,以测量六种活性成分的血度:阿沃松,氧松,八烯,荷马沙酸盐,八酸盐和八酸盐.

主要成果:

  • 所有六种活性成分都被系统吸收,在单次应用后的第一天,血度超过了FDA的0. 5 ng/ ml的值.
  • 血最大度因成分和配方而异,其中氧和同类盐的度特别高.
  • 在14名参与者中,皮疹是最常见的不良反应.

结论:

  • 这项研究证实了四种配方中的六种防晒活性成分的全身吸收.
  • 血度超过了FDA的值,可能会影响未来的安全性研究要求.
  • 这些发现并不意味着人们应该停止使用防晒.